Recommendation ID
Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Date issued
February 2011

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No